Scalper1 News
Brenton Saunders and Paul Bisaro have a lot of experience in making big pharma deals. Since he became CEO of generic drugmaker Watson Pharmaceuticals in 2007, Bisaro has built the company into a giant through its 2012 buyout of Actavis (ACT), whose name Watson adopted, and last year’s purchase of Warner Chilcott, which won the company a low-tax Irish address. Meanwhile, in 2010, Saunders was appointed CEO of Bausch & Lomb, which he sold to Valeant Scalper1 News
Scalper1 News